295 related articles for article (PubMed ID: 20371753)
1. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
3. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
4. Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
Antoniou T; Smith G; Su D; Raboud JM; Lee D; Kovacs C; Brunetta J; Fletcher D; Crouzat F; Loutfy M
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):192-7. PubMed ID: 22247337
[TBL] [Abstract][Full Text] [Related]
5. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
[TBL] [Abstract][Full Text] [Related]
6. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
[TBL] [Abstract][Full Text] [Related]
7. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
[No Abstract] [Full Text] [Related]
8. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S; Galli L; Visco F; Soria A; Canducci F; Salpietro S; Gianotti N; Bigoloni A; Torre LD; Tambussi G; Lazzarin A; Castagna A
AIDS; 2010 Mar; 24(6):924-8. PubMed ID: 20154578
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.
Llibre JM; Rivero A; Rojas JF; Garcia Del Toro M; Herrero C; Arroyo D; Pineda JA; Pasquau J; Masiá M; Crespo M; Blanco JR; Moreno S
Antiviral Res; 2015 Aug; 120():79-84. PubMed ID: 25977241
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
[TBL] [Abstract][Full Text] [Related]
13. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A; Nozza S; Bonora S; Castagna A; Gonzalez de Requena D; D'Avolio A; Lazzarin A; Di Perri G
J Antimicrob Chemother; 2011 Aug; 66(8):1932-4. PubMed ID: 21642649
[No Abstract] [Full Text] [Related]
17. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
18. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Armstrong-James D; Stebbing J; Scourfield A; Smit E; Ferns B; Pillay D; Nelson M
Antiviral Res; 2010 May; 86(2):224-6. PubMed ID: 20211653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
